Dr. Brigitte Poirier is a surgeon-oncologist at the CHU de Québec-Laval University. She is also a clinical researcher at the Research Center of the CHU de Québec-Laval University, and a clinical professor at Laval University School of Medicine. Dr. Poirier is part of the research group of the Centre des Maladies du Sein of CHU de Québec-Laval University.
Using structured breast cancer data
The Centre des Maladies du Sein research team has a comprehensive database of all cancers diagnosed since 1974; more than 12,000 patients are listed. A database of biopsy data from 1999 is also available; data on more than 34,000 biopsies are listed. These databases allow quality publications that modify the management and follow-up of cancers and benign breast diseases.
Offer innovative treatments
The Centre des Maladies du Sein of CHU de Québec-Laval University research group is one of the largest in Canada, offering innovative treatments for breast cancer. More than 50 clinical trials are active at all times and are offered to patients who consult at the clinic or are referred by clinics/hospitals in the area. These clinical trials provide access to innovative experimental medications and develop the expertise of our world-renowned oncologists.
Support the quality of life
The Centre des Maladies du Sein of CHU de Québec-Laval University research group is a pioneer in quality of life studies in breast cancer, from total mastectomy to partial mastectomy, to the use of the cooling cap to counteract hair loss, promoting physical activity to improve survivorship, including optimal preservation of the axillary lymph nodes. The research group is at the forefront of studies promoting quality of life, despite the adverse effects of the disease on an individual’s life.
1050, chemin Sainte-Foy
Centre des maladies du sein Deschênes-Fabia
Canada G1S 4L8
Data not available
Association between expression of inflammatory markers in normal breast tissue and mammographic density among premenopausal and postmenopausal womenJournal Article
Menopause, 24 (5), 2017.
How Wide Should Margins Be for Phyllodes Tumors of the Breast?Journal Article
Breast J, 23 (3), 2017.
Is clinical breast examination important for breast cancer detection?Journal Article
Curr Oncol, 23 (4), 2016.
5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trialJournal Article
Lancet Oncol, 17 (6), 2016.
Is there an Upgrading to Malignancy at Surgery of Mucocele-Like Lesions Diagnosed on Percutaneous Breast Biopsy?Journal Article
Breast J, 22 (2), 2016.
Association of Telomere Length with Breast Cancer Prognostic FactorsJournal Article
PLoS One, 11 (8), 2016.
Five-Year Incidence of Amyotrophic Lateral Sclerosis in British Columbia (2010-2015)Journal Article
Can J Neurol Sci, 43 (6), 2016.
Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: the SN FNAC studyJournal Article
J Clin Oncol, 33 (3), 2015.
Immune modulation of pathologic complete response after neoadjuvant HER2-directed therapies in the NeoSphere trialJournal Article
Ann Oncol, 26 (12), 2015.
Evaluation of eligibility and recruitment in breast cancer clinical trialsJournal Article
Breast, 23 (4), 2014.
- NSABP Breast Cancer Treatment Protocols, from 1997-02-01 to 2025-12-25